fda warning letter hims & hers compounded semaglutide september 2025 stock falls 25% as curtails GLP-1s HIMS offers low-cost oral GLP-1

Real Peptides labels every vial with precise peptide content to eliminate guesswork

Clinical studies show that GLP-1RAs can improve both motor and cognitive symptoms in PD patients, which is a potential breakthrough in the treatment and prevention of PD

While this risk has not been confirmed in human epidemiological studies, patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use orforglipron or any GLP-1 receptor agonist

All post-dose glucose levels remained within the normal reference range for the laboratory, and no adverse events of hypoglycemia were reported